Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 399

1.

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders.

Huang YS, Ogbechi J, Clanchy FI, Williams RO, Stone TW.

Front Immunol. 2020 Mar 5;11:388. doi: 10.3389/fimmu.2020.00388. eCollection 2020. Review.

2.

Consolidation of Imaging Modalities Utilizing Digitally Assisted Visualization Systems: The Development of a Surgical Information Handling Cockpit.

Brooks CC, Kitchens J, Stone TW, Riemann CD.

Clin Ophthalmol. 2020 Feb 27;14:557-569. doi: 10.2147/OPTH.S239339. eCollection 2020.

3.

Dependence and Guidance Receptors-DCC and Neogenin-In Partial EMT and the Actions of Serine Proteases.

Stone TW.

Front Oncol. 2020 Feb 4;10:94. doi: 10.3389/fonc.2020.00094. eCollection 2020. Review.

4.

IDO activation, inflammation and musculoskeletal disease.

Ogbechi J, Clanchy FI, Huang YS, Topping LM, Stone TW, Williams RO.

Exp Gerontol. 2020 Mar;131:110820. doi: 10.1016/j.exger.2019.110820. Epub 2019 Dec 26. Review.

PMID:
31884118
5.

Does kynurenic acid act on nicotinic receptors? An assessment of the evidence.

Stone TW.

J Neurochem. 2020 Mar;152(6):627-649. doi: 10.1111/jnc.14907. Epub 2019 Nov 24. Review.

6.

Serine protease modulation of Dependence Receptors and EMT protein expression.

McNair K, Forrest CM, Vincenten MCJ, Darlington LG, Stone TW.

Cancer Biol Ther. 2019;20(3):349-367. doi: 10.1080/15384047.2018.1529109. Epub 2018 Nov 7.

7.

Long term follow-up study of non-invasive brain stimulation (NBS) (rTMS and tDCS) in Parkinson's disease (PD). Strong age-dependency in the effect of NBS.

Málly J, Stone TW, Sinkó G, Geisz N, Dinya E.

Brain Res Bull. 2018 Sep;142:78-87. doi: 10.1016/j.brainresbull.2018.06.014. Epub 2018 Jun 26.

8.

Obesity and Cancer: Existing and New Hypotheses for a Causal Connection.

Stone TW, McPherson M, Gail Darlington L.

EBioMedicine. 2018 Apr;30:14-28. doi: 10.1016/j.ebiom.2018.02.022. Epub 2018 Feb 27. Review.

9.

PRN Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Ocular Histoplasmosis.

Wood EH, Whitted RJ, Stone TW, Isernhagen RD, Wood WJ, Holcomb DM, Kitchens JW.

Ophthalmic Surg Lasers Imaging Retina. 2018 Jan 1;49(1):20-26. doi: 10.3928/23258160-20171215-03.

PMID:
29304262
10.

Microbial carcinogenic toxins and dietary anti-cancer protectants.

Stone TW, Darlington LG.

Cell Mol Life Sci. 2017 Jul;74(14):2627-2643. doi: 10.1007/s00018-017-2487-z. Epub 2017 Feb 25. Review.

11.

Kynurenine Pathway Activation in Human African Trypanosomiasis.

Sternberg JM, Forrest CM, Dalton RN, Turner C, Rodgers J, Stone TW, Kennedy PGE.

J Infect Dis. 2017 Mar 1;215(5):806-812. doi: 10.1093/infdis/jiw623.

12.

Quinolinic acid induces neuritogenesis in SH-SY5Y neuroblastoma cells independently of NMDA receptor activation.

Hernandez-Martinez JM, Forrest CM, Darlington LG, Smith RA, Stone TW.

Eur J Neurosci. 2017 Mar;45(5):700-711. doi: 10.1111/ejn.13499. Epub 2017 Jan 26.

PMID:
27973747
13.

The Gut-Brain Axis, BDNF, NMDA and CNS Disorders.

Maqsood R, Stone TW.

Neurochem Res. 2016 Nov;41(11):2819-2835. Epub 2016 Aug 23. Review.

PMID:
27553784
14.
15.

Kynurenine pathway metabolism following prenatal KMO inhibition and in Mecp2+/- mice, using liquid chromatography-tandem mass spectrometry.

Forrest CM, Kennedy PG, Rodgers J, Dalton RN, Turner C, Darlington LG, Cobb SR, Stone TW.

Neurochem Int. 2016 Nov;100:110-119. doi: 10.1016/j.neuint.2016.09.012. Epub 2016 Sep 10.

16.

Dependence receptor involvement in subtilisin-induced long-term depression and in long-term potentiation.

Stone TW, Darlington LG, Forrest CM.

Neuroscience. 2016 Nov 12;336:49-62. doi: 10.1016/j.neuroscience.2016.08.043. Epub 2016 Aug 31.

PMID:
27590265
17.

The kynurenine pathway: Towards metabolic equilibrium.

Clarke G, Stone TW, Schwarcz R.

Neuropharmacology. 2017 Jan;112(Pt B):235-236. doi: 10.1016/j.neuropharm.2016.08.029. Epub 2016 Aug 24. No abstract available.

PMID:
27567943
18.

The kynurenine pathway and the brain: Challenges, controversies and promises.

Schwarcz R, Stone TW.

Neuropharmacology. 2017 Jan;112(Pt B):237-247. doi: 10.1016/j.neuropharm.2016.08.003. Epub 2016 Aug 7. Review.

19.

Tryptophan and kynurenines: continuing to court controversy.

Stone TW.

Clin Sci (Lond). 2016 Aug 1;130(15):1335-7. doi: 10.1042/CS20160294.

PMID:
27358029
20.

Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine.

Forrest CM, McNair K, Pisar M, Khalil OS, Darlington LG, Stone TW.

Neuroscience. 2015 Dec 3;310:91-105. doi: 10.1016/j.neuroscience.2015.09.022. Epub 2015 Sep 10.

21.

Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.

Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW; Diabetic Retinopathy Clinical Research Network.

Ophthalmology. 2015 Feb;122(2):375-81. doi: 10.1016/j.ophtha.2014.08.047. Epub 2014 Oct 28.

22.

Protection by the flavonoids quercetin and luteolin against peroxide- or menadione-induced oxidative stress in MC3T3-E1 osteoblast cells.

Fatokun AA, Tome M, Smith RA, Darlington LG, Stone TW.

Nat Prod Res. 2015;29(12):1127-32. doi: 10.1080/14786419.2014.980252. Epub 2014 Nov 26.

PMID:
25427161
23.

Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway.

Pisar M, Forrest CM, Khalil OS, McNair K, Vincenten MC, Qasem S, Darlington LG, Stone TW.

Brain Res. 2014 Aug 12;1576:1-17. doi: 10.1016/j.brainres.2014.06.016. Epub 2014 Jun 21.

PMID:
24956103
24.

Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring.

Khalil OS, Pisar M, Forrest CM, Vincenten MC, Darlington LG, Stone TW.

Eur J Neurosci. 2014 May;39(10):1558-71. doi: 10.1111/ejn.12535. Epub 2014 Mar 19.

25.

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration.

Kitchens JW, Kassem N, Wood W, Stone TW, Isernhagen R, Wood E, Hancock BA, Radovich M, Waymire J, Li L, Schneider BP.

Clin Ophthalmol. 2013;7:1987-93. doi: 10.2147/OPTH.S39635. Epub 2013 Oct 10.

26.

Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway.

Forrest CM, Khalil OS, Pisar M, McNair K, Kornisiuk E, Snitcofsky M, Gonzalez N, Jerusalinsky D, Darlington LG, Stone TW.

Neuroscience. 2013 Dec 19;254:241-59. doi: 10.1016/j.neuroscience.2013.09.034. Epub 2013 Sep 25.

PMID:
24076085
27.

Prenatal activation of maternal TLR3 receptors by viral-mimetic poly(I:C) modifies GluN2B expression in embryos and sonic hedgehog in offspring in the absence of kynurenine pathway activation.

Khalil OS, Forrest CM, Pisar M, Smith RA, Darlington LG, Stone TW.

Immunopharmacol Immunotoxicol. 2013 Oct;35(5):581-93. doi: 10.3109/08923973.2013.828745. Epub 2013 Aug 28.

PMID:
23981041
28.

The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Stone TW, Darlington LG.

Br J Pharmacol. 2013 Jul;169(6):1211-27. doi: 10.1111/bph.12230. Review.

29.

Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus.

Forrest CM, Khalil OS, Pisar M, Darlington LG, Stone TW.

Brain Res. 2013 Apr 4;1504:1-15. doi: 10.1016/j.brainres.2013.01.031. Epub 2013 Jan 24.

PMID:
23353758
30.

Involvement of the proteasome and caspase activation in hippocampal long-term depression induced by the serine protease subtilisin.

Forrest CM, Darlington LG, Stone TW.

Neuroscience. 2013 Feb 12;231:233-46. doi: 10.1016/j.neuroscience.2012.11.029. Epub 2012 Dec 1.

PMID:
23206873
31.

An expanding range of targets for kynurenine metabolites of tryptophan.

Stone TW, Stoy N, Darlington LG.

Trends Pharmacol Sci. 2013 Feb;34(2):136-43. doi: 10.1016/j.tips.2012.09.006. Epub 2012 Nov 1. Review.

PMID:
23123095
32.

Effects of ethylenediamine in rodent models of seizure, motor coordination and anxiety.

Addae JI, Walkins K, Cruickshank R, Stone TW.

Brain Res. 2012 Sep 14;1473:155-60. doi: 10.1016/j.brainres.2012.07.019. Epub 2012 Jul 20.

PMID:
22820302
33.

A novel dihydro-pyrazolo(3,4d)(1,2,4)triazolo(1,5a)pyrimidin-4-one (AJ23) is an antagonist at adenosine A(1) receptors and enhances consolidation of step-down avoidance.

Harvey AL, Young LC, Kornisiuk E, Snitcofsky M, Colettis N, Blanco C, Jerusalinsky D, Jamieson AG, Hartley RC, Stone TW.

Behav Brain Res. 2012 Oct 1;234(2):184-91. doi: 10.1016/j.bbr.2012.06.023. Epub 2012 Jun 28.

PMID:
22750535
34.
35.

Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.

Stone TW, Forrest CM, Darlington LG.

FEBS J. 2012 Apr;279(8):1386-97. doi: 10.1111/j.1742-4658.2012.08487.x. Epub 2012 Mar 27. Review.

36.

Altered apoptotic responses in neurons lacking RhoB GTPase.

Barberan S, McNair K, Iqbal K, Smith NC, Prendergast GC, Stone TW, Cobb SR, Morris BJ.

Eur J Neurosci. 2011 Dec;34(11):1737-46. doi: 10.1111/j.1460-9568.2011.07891.x. Epub 2011 Nov 18.

37.

The serine protease subtilisin suppresses epileptiform activity in rat hippocampal slices and neocortex in vivo.

Addae JI, Stone TW.

Neuroscience. 2011 Dec 29;199:64-73. doi: 10.1016/j.neuroscience.2011.10.014. Epub 2011 Oct 19.

PMID:
22033457
38.

Molecular changes associated with hippocampal long-lasting depression induced by the serine protease subtilisin-A.

Forrest CM, Addae JI, Murthy S, Darlington LG, Morris BJ, Stone TW.

Eur J Neurosci. 2011 Oct;34(8):1241-53. doi: 10.1111/j.1460-9568.2011.07853.x.

PMID:
21999580
39.

Kynurenine metabolism predicts cognitive function in patients following cardiac bypass and thoracic surgery.

Forrest CM, Mackay GM, Oxford L, Millar K, Darlington LG, Higgins MJ, Stone TW.

J Neurochem. 2011 Oct;119(1):136-52. doi: 10.1111/j.1471-4159.2011.07414.x. Epub 2011 Sep 1.

40.

Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.

Stone TW, Forrest CM, Stoy N, Darlington LG.

J Neural Transm (Vienna). 2012 Feb;119(2):261-74. doi: 10.1007/s00702-011-0676-8. Epub 2011 Jun 22. Review.

PMID:
21695417
41.

Memory impairment in rats by hippocampal administration of the serine protease subtilisin.

Kornisiuk E, Snitcofsky M, Blanco C, Harvey AL, Stone TW, Jerusalinsky D.

Behav Brain Res. 2011 May 16;219(1):63-7. doi: 10.1016/j.bbr.2010.12.027. Epub 2010 Dec 24.

PMID:
21185873
42.

Effects of AMPA and clomethiazole on spreading depression cycles in the rat neocortex in vivo.

Addae JI, Ali N, Stone TW.

Eur J Pharmacol. 2011 Feb 25;653(1-3):41-6. doi: 10.1016/j.ejphar.2010.11.021. Epub 2010 Dec 11.

PMID:
21147095
43.

Effects of ethylenediamine--a putative GABA-releasing agent--on rat hippocampal slices and neocortical activity in vivo.

Stone TW, Lui C, Addae JI.

Eur J Pharmacol. 2011 Jan 15;650(2-3):568-78. doi: 10.1016/j.ejphar.2010.10.061. Epub 2010 Nov 2.

PMID:
21050846
44.

Glutamate-induced depression of EPSP-spike coupling in rat hippocampal CA1 neurons and modulation by adenosine receptors.

Ferguson AL, Stone TW.

Eur J Neurosci. 2010 Apr;31(7):1208-18. doi: 10.1111/j.1460-9568.2010.07157.x. Epub 2010 Mar 19.

PMID:
20345917
45.

A role for RhoB in synaptic plasticity and the regulation of neuronal morphology.

McNair K, Spike R, Guilding C, Prendergast GC, Stone TW, Cobb SR, Morris BJ.

J Neurosci. 2010 Mar 3;30(9):3508-17. doi: 10.1523/JNEUROSCI.5386-09.2010. Erratum in: J Neurosci. 2017 Sep 20;37(38):9346.

46.

On the Biological Importance of the 3-hydroxyanthranilic Acid: Anthranilic Acid Ratio.

Darlington LG, Forrest CM, Mackay GM, Smith RA, Smith AJ, Stoy N, Stone TW.

Int J Tryptophan Res. 2010;3:51-9. Epub 2010 Jun 10.

47.

Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.

Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann BD, Stone TW; Diabetic Retinopathy Clinical Research Network.

Arch Ophthalmol. 2009 Dec;127(12):1566-71. doi: 10.1001/archophthalmol.2009.308.

48.

Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease.

Forrest CM, Mackay GM, Stoy N, Spiden SL, Taylor R, Stone TW, Darlington LG.

J Neurochem. 2010 Jan;112(1):112-22. doi: 10.1111/j.1471-4159.2009.06442.x. Epub 2009 Oct 20.

49.

Preconditioning with 4-aminopyridine protects cerebellar granule neurons against excitotoxicity.

Smith AJ, Tauskela JS, Stone TW, Smith RA.

Brain Res. 2009 Oct 19;1294:165-75. doi: 10.1016/j.brainres.2009.07.061. Epub 2009 Jul 28.

PMID:
19643095
50.

Adenosine receptors and neurological disease: neuroprotection and neurodegeneration.

Stone TW, Ceruti S, Abbracchio MP.

Handb Exp Pharmacol. 2009;(193):535-87. doi: 10.1007/978-3-540-89615-9_17. Review.

PMID:
19639293

Supplemental Content

Loading ...
Support Center